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Background: Topotecan is an active agent for relapsed or recurrent 
SCLC. Combination chemotherapy of topotecan and carboplatin for re-
lapsed SCLC has not been fully evaluated. To determine the maximum-
tolerated dose (MTD), a phase I study was conducted. 
Method: Patients with measurable disease and one prior chemotherapy 
regimen excluding topotecan were enrolled in this study. Topotecan 
was administered through days 1 to 5, whereas carboplatin was admin-
istered on day 5. Courses were repeated every 3 weeks. The starting 
doses of topotecan and carboplatin were 0.50 mg/m2/day and AUC=5, 
respectively. The dose levels examined are shown in the table below. 
Results: A total of 32 patients with relapsed SCLC have been enrolled. 
Patient characteristics are as follows: median age, 64 yrs (range 43-74); 
male/female, 23/9; ECOG PS 0/1, 15/17 patients. Dose-limiting toxici-
ties (DLTs) were observed in 1 patient at dose level 1 (infection), level 
3 (diarrhea), and level 5 (thrombocytopenia), respectively. Three of 6 
patients have experienced DLTs at dose level 6 (thrombocytopenia). 
MTD of topotecan and carboplatin were determined to be 0.85 mg/m2 
and AUC=5, respectively. Five of 29 (17%) assessable patients have 
responded to treatment with a partial response (PR), and 13 (45%) 
patients have had stable disease (SD) at best response. 
Conclusions: The recommended doses are 0.75mg/m2 of topotecan and 
AUC=5 of carboplatin. The combination of topotecan and carboplatin 
shows an acceptable activity and toxicity proﬁle in relapsed SCLC 
patients. Further study in the phase III setting is warranted.
Level (no. of pts.)
Topotecan (mg/m2)/ 
Carboplatin (AUC)
Cycle 1 DLTs Responses (PR/SD)
1 (n=6) 0.50/5 1 0/2
2 (n=3) 0.60/5 0 0/1
3 (n=8) 0.65/5 1 2/2
4 (n=3) 0.70/5 0 0/3
5 (n=6) 0.75/5 1 0/4
6 (n=6) 0.85/5 3 3/1
Total (n=32) 6 5/13
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Background: Clinical studies of P have shown less overall toxicity and 
reductions in Grades 3/4 hematologic and nonhematologic toxicities 
when pts are pretreated with folic acid and Vitamin B
12
. Current recom-
mendations are to give folic acid 350 µg to 1000 µg by mouth for at 
least 5 of 7 days prior to the 1st dose of P, and 1 injection of Vitamin 
B
12
 1000 µg during the week preceding the 1st P dose. Treatment delay 
to allow this supplementation may be clinically undesirable, particular-
ly in pts with aggressive malignancies. A trial evaluating single-agent P 
for the treatment of relapsed SCLC gave us opportunity to observe the 
effects of a shortened lead-in time for vitamin supplementation.
Methods: We reviewed data from a US trial designed to assess the 
safety and efﬁcacy of single-agent P in chemosensitive and chemore-
fractory relapsed SCLC pts. Eligible pts had limited or extensive-stage 
SCLC, PS 0 to 2, and 1 prior chemo regimen. Pts received P doses of 
500 mg/m2 or 900 mg/m2 q 21 d. The protocol required the administra-
tion of folic acid for at least 5 of 7 days prior to the 1st P dose, and 
Vitamin B
12
 administration on Day 1, Cycle 1, or up to 14 days prior to 
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the 1st P dose. Adverse events were tabulated using Coding Symbols 
for Thesaurus of Adverse Reaction Terms (COSTART) terminology. 
Included in the analysis were pts who received at least 1 dose of folic 
acid prior to 1st P dose. We analyzed preliminary toxicity results for pts 
receiving Vitamin B
12
 for 0-3, 4-6 and ≥7 days prior to 1st P dose.
Results: From 7/04 to 3/06, 116 pts were treated with P. M/F 57/59; 
median age 64.5 (range 35-85); PS 0/1/2 39/57/20. Because toxicities 
observed between the two P doses were not signiﬁcantly different, the 
combined toxicities for both dosing groups are reported in the table.
Conclusions: B
12
 given less than 7 days prior to P does not appear to be 
associated with increased serious toxicities.
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Determining of tumour markers in detecting a malignant disease is of 
little importance; they serve for follow-up and forecast of a disease. 
Presuming that for the patient suffering from SCLC determining of 
NSE has important speciﬁcity and diagnostic sensitivity, we followed-
up 20 patients with the diagnosed SCLC, during the treatment with 
the ﬁrst line of polychemotherapeutic guidelines platinum - etoposid. 
NSE values were determined before the treatment, as well as after the 
3rd and 6th cycle of treatment. The results were compared with the 
treatment response that was analyzed according to the radiological, 
endoscopic and clinical ﬁnding. The average NSE value before the 
treatment was 94,1. In 16 patients with the therapeutic response, the av-
erage NSE value before the treatment was 74,1, and after 3 conducted 
therapeutic cycles 39,6. Four patients with disease progression had av-
erage NSE values of 183,5 before the treatment; and after 3 conducted 
cycles 111,9. In 9 patients there was disease progression after the 6-
cycle treatment. Before the treatment, the average NSE values in these 
patients were 162,3; after 3 cycles 89,9 and after the entire treatment 
134,3. The results obtained prove that the NSE values during the treat-
ment are in direct correlated with the therapeutic response, i.e. increase 
of NSE values during the treatment conﬁrm the progression of the dis-
ease. Patients with the initially high NSE values have worse forecast. 
NSE could be used in disease follow-up for the clinical purposes. 
P1-231 SCLC: Cytotoxic Chemotherapy Posters, Mon, Sept 3 
The development of recurrence and metachronous tumor after 
treatment in a case with small cell lung carcinoma
Turan, Onur1 Akkoclu, Atila1 Kargi, Aydanur2 Osma, Emine3 
1 Dokuz Eylul University the Faculty of Medicine Chest Diseases De-
partment, Izmir, Turkey 2 Dokuz Eylul University the Faculty of Medi-
cine Pathology Department, Izmir, Turkey 3 Dokuz Eylul University the 
Faculty of Medicine Radiology Department, Izmir, Turkey 
Small cell lung cancer (SCLC) is a kind of disease with a good 
response to chemotherapy. Although it is highly responsive to chemo-
therapy and radiotherapy, it usually recurs within a few years and the 
most important causes of mortality are relapses and second primary 
tumors in these patients. A sixty-two-year old male patient was referred 
to hospital with the complaint of back pain. A mass lesion was found 
in the upper lobe of the left lung which was diagnosed as SCLC by 
anterior mediastinotomy and it was deﬁned as limited disease SCLC 
after staging evaluations. After carboplatin-etoposide chemotherapy 
and radiotherapy, it was detected that there was total regression at the 
lesion. During follow-up periods, a new right pulmonary mass ap-
peared in thoracic CT scan which had the diagnosis of adenocarcinoma 
by a transthoracic needle biopsy. So, it was accepted as a metachronous 
lung carcinoma; and the patient had a new chemotherapy regimen 
including carboplatin and gemsitabine because of the diagnosis of 
non small cell lung cancer (NSCLC). There was a good response to 
chemotherapy again and the metachronous tumor totally regressed. 
During the controls of the patient, there was a left hilar mass found at 
the same localization with the ﬁrst SCLC lesion. The case was thought 
as a recurrence of SCLC this time and the prior chemotherapy was 
executed again; carboplatin and etoposide. With the development 
of metachronous tumor and recurrence in a short time, which is an 
unexpected behaviour of the tumor, and with the perfect response to the 
platin based chemotherapy at every attack of the tumor, we would like 
to present this interesting case. 
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A 65-year-old woman without smoking history was admitted to our 
hospital with cough, sputum, hemoptysis, dyspnea and weight loss. At 
the chest X-ray, a right hilar mass lesion and a right - sided pleural effu-
sion were seen. Thorax CT revealed a paracardiac mass with a size of 7 
x 10 cm at the right lung invading right atrium and mediastinum. Fiber-
optic bronchoscopy showed a fragile lesion with an irregular mucosa in 
intermediary bronchus of the right lung. Bronchial lavage and sputum 
smears were positive for acid-fast bacilli. The bronchial mucosa biopsy 
revealed a small cell lung carcinoma (SCLC). So our patient had two 
diagnoses synchronously; SCLC and active pulmonary tuberculosis. 
We have started antituberculosis therapy with four agents (H,R,Z and 
E). 15 days later, cisplatinum-etoposide chemotherapy with a 25 % 
reduced dose was given to her. Antituberculosis and cytotoxic therapies 
were executed at the same time and the patient tolerated it well. After 
a month of antituberculosis treatment, her sputum smear for acid-fast 
bacilli became negative. After two cures of chemotherapy, there was a 
regression of nearly 90 % of the mass at the thorax CT and her clinical 
status became better. Although pulmonary tuberculosis can coexist 
with lung cancer, few cases of SCLC and pulmonary tuberculosis have 
been reported together. The cytotoxic therapy of SCLC can have an 
immunsupressive effect which is a negative progress for tuberculosis, 
and antituberculosis therapy can increase the toxic events of chemo-
therapy; these conditions can be a problem for the clinician. Also, there 
is a little literature information about the therapy used at this situation. 
Regarding the rare coexistence of these diseases, a good tolerance of 
cytotoxic and antituberculosis therapy despite the old age, and with a 
perfect clinical and radiological response as a result, we considered to 
present this case.
